Aptorum Group is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs. In addition, Co. is also pursuing in the therapeutic projects in neurology, gastroenterology, metabolic disorders, women's health and other disease areas. Co.'s Lead Projects are: ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus including but not limited to Methicillin-resistant Staphylococcus aureus; SACT-1, repurposed frug for the treatment of Neuroblastoma; and RPIDD, a molecular-based rapid pathogen identification and detection diagnostics technology. We show 3 historical shares outstanding datapoints in our coverage of APM's shares outstanding history.
Understanding the changing numbers of APM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like APM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching APM by allowing them to research APM shares outstanding history
as well as any other stock in our coverage universe. |
Free APM Email Alerts:
Video: Shares Outstanding Importance
